Pulmonary Arterial Hypertension

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Latest News

Melatonin | Image Credit: JEGAS RA-stock.adobe.com
Melatonin's Role in PAH Treatment Needs More Research

June 27th 2025

Previous knowledge on melatonin use for pulmonary arterial hypertension has primarily been gathered from animal studies, with oxidative stress implicated in the disease’s progression and severity.

Family discussion on PAH care | Image Credit: Maggie L. Shaw/sora.chatgpt.com
Family Key to PAH Care for Women, but Gaps Remain

June 18th 2025

Echocardiography | Image Credit: Tamer-stock.adobe.com
TPIP a Potential Game-Changer for Prostanoid Therapy in PAH

June 11th 2025

Anjali Vaidya, MD, FACC, FASE, FACP | Image Credit: Temple University Hospital
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide

June 4th 2025

PAH X-ray with pen | Image credit: Dzmitry – stock.adobe.com
Sotatercept for PAH Maintains Safety, Reduced Mortality in Long-Term Follow-Up

May 30th 2025

Transforming PAH Management Through Innovation and Strategic Care

Learn how novel therapies, early diagnosis, and personalized treatment approaches are advancing PAH care while addressing clinical needs, patient preferences, and economic impact.

AJMC Stakeholder Summit logo displayed on a light blue and white scientific background with hexagonal molecular graphics and connecting lines.

More News

Researchers Describe Clinical Features of TAK With PAI
December 19th 2021

Researchers Describe Clinical Features of TAK With PAI

Jaime Rosenberg
Drawing a clearer picture of the relationship between pulmonary artery involvement (PAI) in Takayasu arteritis (TAK), researchers have published data on the clinical features of TAK with PAI.
Review Provides Overview of Pulmonary Arterial Hypertension
December 15th 2021

Review Provides Overview of Pulmonary Arterial Hypertension

Allison Inserro
Pulmonary arterial hypertension is a rare form of pulmonary hypertension that poses diagnostic challenges and often comes with a delayed diagnosis.
Use Liver Fibrosis Index for Hints About PAH Progression, Study Says
December 13th 2021

Use Liver Fibrosis Index for Hints About PAH Progression, Study Says

Allison Inserro
The researchers said they believe it is the first study to show the presence of hepatic fibrosis in patients with chronic right heart failure accompanied by pulmonary arterial hypertension (PAH) using liver ultrasound elastography.
To Improve Outcomes, Identify Predictive Factors of PAH Earlier in Patients With SLE, Study Says
December 10th 2021

To Improve Outcomes, Identify Predictive Factors of PAH Earlier in Patients With SLE, Study Says

Allison Inserro
Although pulmonary arterial hypertension (PAH) is a rare occurrence in systemic lupus erythematosus (SLE), a recent report details efforts by researchers to find an easy way to identify predictive factors, since having both diseases together reduces overall survival.
Image of a tapeworm
November 27th 2021

Review: More Investigation Needed to Understand Pathogenesis of Sch-PAH

Lauren Massaro
Further investigation on the pathogenesis and treatment of patients with schistosome-associated pulmonary arterial hypertension (Sch-PAH) may lead to improved symptoms and higher rates of survival.
heart graphic
November 22nd 2021

Macitentan Associated With Right Ventricular Function, Structure Improvement in PAH

Gianna Melillo
REPAIR study findings outline the benefits of macitentan for right ventricular functioning in pulmonary arterial hypertension.
lung graphic
November 20th 2021

Review: More Research Needed on Immune System to Understand PAH Pathobiology

Lauren Massaro
While research has examined the implications of the immune system and its contributions to pulmonary arterial hypertension, further research is required to understand the pathobiology of the condition.
patients graphic
November 19th 2021

Study Determines PAH-SYMPACT Suitable for Use Among Patients With SAPH

Lauren Massaro
A new study aiming to understand sarcoidosis-associated pulmonary hypertension symptoms and their impacts on patients’ lives determined that the Pulmonary Arterial Hypertension-Symptoms and Impact questionnaire could be used to suitably assess patients.
blood in vials
November 12th 2021

Study Identifies Potential Noninvasive Biomarkers for PAH Severity

Gianna Melillo
Researchers in Japan identified 2 potential biomarkers for severity of pulmonary arterial hypertension (PAH) that can be measured without invasive procedures.
diversity graphic
November 8th 2021

Researchers Push for Improved Racial Representation in PAH Registries, RCTs

Gianna Melillo
Researchers outlined the need to combat underrepresentation of racial minorities in pulmonary arterial hypertension (PAH) registries and trials.
Patients With CTEPH Have Worse Baseline HRQOL Than Patients With IPAH
November 6th 2021

Patients With CTEPH Have Worse Baseline HRQOL Than Patients With IPAH

Laura Joszt, MA
At baseline, patients with chronic thromboembolic pulmonary hypertension (CTEPH) had worse health-related quality of life (HRQOL) than patients with idiopathic pulmonary arterial hypertension (IPAH), but over time the scores were similar.
pills and syringe
November 1st 2021

Analysis: Macitentan May Reduce Morbidity, Mortality of Patients With PAH on Spironolactone

Gianna Melillo
Patients with pulmonary arterial hypertension (PAH) taking spironolactone saw a reduced risk of morbidity and mortality when receiving macitentan 10 mg.
blue cross
October 30th 2021

Case Highlights Importance of Screening for Systemic Sclerosis in PAH, Raynaud

Gianna Melillo
A case study highlights the important role of nailfold videocapillaroscopy assessments in patients with Raynaud disease and pulmonary arterial hypertension (PAH).
pregnant woman
October 25th 2021

Meta-analysis Finds Local Anesthesia Superior During Cesarean Delivery in Women With PAH

Gianna Melillo
Local anesthesia yields superior outcomes in pregnant women with pulmonary arterial hypertension (PAH) undergoing cesarean deliveries compared with general anesthesia.
cancer cells
October 20th 2021

Case Series Highlights Importance of PAH Screening in Pediatric Cancer

Gianna Melillo
A case series underscores the importance of pulmonary arterial hypertension (PAH) screening in pediatric patients undergoing chemotherapy and stem cell transplantation.
lung graphic
October 18th 2021

Biomarker May Help Improve Mortality Risk Prediction in PAH

Gianna Melillo
Endostatin could help measure pulmonary arterial hypertension (PAH) severity.
lung graphic
October 15th 2021

Case Study: Modified Potts Shunt Yields Exercise Benefit in Patient With PAH

Gianna Melillo
A patient with pulmonary arterial hypertension (PAH) who received a modified Potts shunt exhibited improved quality of life and exercise capacity after 1 year.
tech icon
October 13th 2021

Study Tests Feasibility of Remote Monitoring in PAH

Gianna Melillo
Researchers tested the feasibility of remote monitoring for patients with pulmonary arterial hypertension via smartphones and smartwatches.
PAH-affected lungs
October 6th 2021

Triplet Therapy for PAH May Reduce Disease Progression vs Doublet Therapy

Maggie L. Shaw
New data on treatment for newly diagnosed pulmonary arterial hypertension (PAH) show initial treatment for the progressive disease that includes macitentan has potential to reduce risk of disease progression.
Oral Selexipag Offers New Therapy Option in PAH-CHD, Case Reports Show
May 18th 2021

Oral Selexipag Offers New Therapy Option in PAH-CHD, Case Reports Show

Jared Kaltwasser
A series of 5 cases highlights different opportunities to incorporate selexipag into the care of patients with pulmonary arterial hypertension, potentially eliminating risks associated with parenteral prostacyclin.
New Analysis Identifies Prognostic Indicators in Pulmonary Hypertension Secondary to HFrEF
May 13th 2021

New Analysis Identifies Prognostic Indicators in Pulmonary Hypertension Secondary to HFrEF

Jared Kaltwasser
Right ventricular end-systolic elastance to end-systolic arterial elastance coupling in excess of 0.68 was linked with preserved right ventricular function and better survival outcomes in patients with heart failure with reduced ejection fraction and secondary pulmonary hypertension.
graphic of a heart
May 7th 2021

Study: Inhaled Levosimendan Non-Inferior to IV Administration in Pediatric Surgery

Jared Kaltwasser
In a first-of-its kind study, young children undergoing heart surgery had similar results regardless of whether they received levosimendan intravenously or via inhalation.
Monotherapy or Combo Therapy for Older Patients With PAH and Multiple Comorbidities?
April 30th 2021

Monotherapy or Combo Therapy for Older Patients With PAH and Multiple Comorbidities?

Laura Joszt, MA
Patients with pulmonary arterial hypertension (PAH) who have comorbidities or advanced age who are treated with a monotherapy have comparable outcomes to patients on combination therapies.
Text Messages Can Successfully Increase Step Counts for Patients With PAH
April 27th 2021

Text Messages Can Successfully Increase Step Counts for Patients With PAH

Laura Joszt, MA
A text message–based intervention successfully increased step counts for patients with pulmonary arterial hypertension (PAH).
Patients With PAH Can Safely Transition From Bosentan and Sildenafil to Alternative Therapy
April 21st 2021

Patients With PAH Can Safely Transition From Bosentan and Sildenafil to Alternative Therapy

Laura Joszt, MA
While bosentan and sildenafil is a common combination therapy in patients with pulmonary arterial hypertension (PAH), patients may need to transition to alternative therapy because of the potential for drug-drug interactions with this combination.
Educational Support Can Improve Compliance to Oral PAH Therapies
April 18th 2021

Educational Support Can Improve Compliance to Oral PAH Therapies

Laura Joszt, MA
An educational nursing program can positively impact medication compliance in patients receiving oral pulmonary arterial hypertension (PAH) therapies.
hospital hallway
April 15th 2021

PAH Treatment Patterns and Costs Related to Hospitalization

Laura Joszt, MA
New research presented at AMCP 2021, the annual meeting of the Academy of Managed Care Pharmacy, evaluated treatment patterns and costs related to hospitalization for patients with pulmonary arterial hypertension (PAH).
Better Understanding of Potential Genetic Mutations May Lead to Improved PAH Diagnosis, Treatment
April 13th 2021

Better Understanding of Potential Genetic Mutations May Lead to Improved PAH Diagnosis, Treatment

Laura Joszt, MA
A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.
Assessing Nutritional Risk Can Predict PAH Prognosis at First Hospitalization
April 6th 2021

Assessing Nutritional Risk Can Predict PAH Prognosis at First Hospitalization

Laura Joszt, MA
Adjunct nutritional therapies may be a simple way to improve the prognosis for patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension who are hospitalized.
SPHERE Registry Provides Snapshot of Selexipag to Treat PAH in the Real World
April 5th 2021

SPHERE Registry Provides Snapshot of Selexipag to Treat PAH in the Real World

Laura Joszt, MA
Registry of patients with pulmonary arterial hypertension (PAH) treated with selexipag provides insights into real-world dosing regimens and outcomes.
<1
...
3456789>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo